レコルダティ、エジャイモ®のグローバル権利取得に合意し、希少疾患事業を強化
October 04, 2024 05:07 ET
|
Recordati
レコルダティ、エジャイモ®のグローバル権利取得に合意し、希少疾患事業を強化 ミラノ、2024年10月4日 – レコルダティは本日、サノフィとエジャイモ®（スチムリマブ）のグローバル権利を取得する契約を締結したことを発表しました。エジャイモ®は、寒冷凝集素症（CAD: Cold Agglutinin Disease）という希少なB細胞リンパ増殖性疾患の治療において唯一承認された生物学的製剤です。 ...
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE
October 04, 2024 01:45 ET
|
Recordati
Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the...
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING
March 23, 2021 04:00 ET
|
RECORDATI
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL...
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE
March 23, 2021 04:00 ET
|
RECORDATI
RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE ...
RECORDATI: RISULTATI PRELIMINARI 2020 CONFERMANO LA CONTINUA CRESCITA DEGLI UTILI OPERATIVI E UTILI NETTI. EBITDA +4,7% E UTILE NETTO RETTIFICATO +7,3%
February 22, 2021 07:20 ET
|
RECORDATI
RECORDATI: RISULTATI PRELIMINARI 2020 CONFERMANO LA CONTINUA CRESCITA DEGLI UTILI OPERATIVI E UTILI NETTI. EBITDA +4,7% E UTILE NETTO RETTIFICATO +7,3% Ricavi netti consolidati € 1.448,9 milioni,...
RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%.
February 22, 2021 07:20 ET
|
RECORDATI
RECORDATI: PRELIMINARY 2020 RESULTS CONFIRM CONTINUED GROWTH OF OPERATING INCOME AND NET INCOME. EBITDA +4.7% AND ADJUSTED NET INCOME +7.3%. Consolidated revenues € 1,448.9 million, -2.2% (+0.4% at...
RECORDATI: OTTENUTA LICENZA PER LA COMMERCIALIZZAZIONE DI ELIGARD® IN EUROPA E ALTRI PAESI
January 29, 2021 12:11 ET
|
RECORDATI
RECORDATI: OTTENUTA LICENZA PER LA COMMERCIALIZZAZIONE DI ELIGARD® IN EUROPA E ALTRI PAESI Milano, 29 gennaio 2021 - Recordati annuncia il perfezionamento di un accordo di Licenza e Fornitura con...
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES
January 29, 2021 12:11 ET
|
RECORDATI
RECORDATI: LICENSE OBTAINED FOR THE COMMERCIALIZATION OF ELIGARD IN EUROPE AND OTHER COUNTRIES Milan, 29 January 2021 – Recordati announces the closing of a License and Supply Agreement with...
RECORDATI: ACCETTATA DALLA EUROPEAN MEDICINES AGENCY LA PRESENTAZIONE DELLA RICHIESTA DI AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO PER ARS-1 (SPRAY NASALE A BASE DI EPINEFRINA)
November 30, 2020 08:00 ET
|
RECORDATI
RECORDATI: ACCETTATA DALLA EUROPEAN MEDICINES AGENCY LA PRESENTAZIONE DELLA RICHIESTA DI AUTORIZZAZIONE ALL’IMMISSIONE IN COMMERCIO PER ARS-1 (SPRAY NASALE A BASE DI EPINEFRINA) Milano, 30 novembre,...
RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY
November 30, 2020 08:00 ET
|
RECORDATI
RECORDATI: MARKET AUTHORIZATION APPLICATION FOR ARS-1 (EPINEPHRINE NASAL SPRAY) ACCEPTED BY EUROPEAN MEDICINES AGENCY Milan, 30 November 2020 – Recordati announces that the European Medicines Agency...